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Aims. The aim of this study was to determine the prognostic significance of HER2 receptor expression in operable oesophagogastric
adenocarcinoma. Methods. Eighty-five consecutive patients diagnosed with oesophagogastric adenocarcinoma [18 oesophageal
(OC), 32 junctional (JC) and 35 gastric (GC)] undergoing potentially curative resection were studied retrospectively. Immuno-
histochemistry was used to determine HER2 status at endoscopic biopsy and resection specimen. The primary outcome measure
was survival. Results. Twenty (24%) patients had HER2 positive tumours which was commoner in JC (14/32, 44% versus 2/18,
11% in OC and 4/35, 11% in GC, P = 0.003). The sensitivity, specificity, positive and negative predictive values of HER2 status
at endoscopic biopsy were 56%, 93%, 63%, 91% respectively (weighted Kappa = 0.504, P < 0.0001). Five-year survival in OC
HER2 positive negative was 100% and 36% (P = 0.167) compared with 14% and 44% (P = 0.0726) in JC and 50% and 46%
(P = 0.942) in GC respectively. Conclusions. Endoscopic biopsy had a high specificity and negative predictive value in determining
HER2 status. Patients with JC had a significantly higher rate of HER2 overexpression and this was associated with a nonsignificant
poorer survival trend. A larger study is needed to confirm these findings because of the implications for neoadjuvant and adjuvant
chemotherapy regimens.
1. Introduction
The worldwide burden of oesophagogastric cancer is grow-
ing. Each year 482,300 and 989,600 people are diagnosed
with oesophageal and gastric cancer resulting in 406,000
and 738,00 deaths, respectively [1]. The optimal contem-
porary treatment is controversial and opinion divided. In
oesophageal cancer, following the publication of the MRC
OEO2 trial, neoadjuvant chemotherapy followed by surgery
is the standard of care for patients with operable oesophageal
cancer [2] in the United Kingdom, whereas neoadjuvant
chemoradiotherapy followed by surgery is the preferred
modality in Europe and the United States [3]. Moreover,
the optimum treatment for patients diagnosed with gastric
cancer in the UK remains controversial, both in terms
of neoadjuvant chemotherapy [4] and the extent of the
lymphadenectomy. However, overall survival reports remain
poor and no established global standard for treatment
exists. New therapies which target specific genetic alterations
arguably oﬀer the best chance for improving patient survival.
The human epidermal growth factor receptor 2 (HER2)
gene is a protooncogene which is located on chromosome
17q11.2–12 and encodes a transmembrane tyrosine kinase
receptor which is responsible for cell growth, diﬀerentiation,
migration, and apoptosis [5]. HER2 is involved in the
development of numerous types of cancer and is overex-
pressed in up to 25% of breast cancer patients, conferring
a poor prognosis [6]. In oesophagogastric cancer, HER2
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overexpression has been reported at frequencies similar to
those observed in breast cancer, ranging from 16% to 27%
[7–10].
A combination of the monoclonal antibody against
HER2 (trastuzumab) with standard chemotherapy improved
survival significantly in patients with HER2 positive
advanced gastric cancer in the Trastuzumab for Gastric
Cancer (ToGA) trial [11]. All patients in this trial had
inoperable junctional or gastric adenocarcinoma and there is
currently no evidence for the use of trastuzumab in operable
HER2 positive oesophagogastric cancer in the neoadjuvant
setting prior to surgery.
The relationship between HER2 overexpression and
prognosis in operable oesophgogastric cancer is controversial
[12, 13]. Some studies have suggested that HER2 overexpres-
sion is associated with poor survival in oesophageal [14, 15]
and gastric cancer [7, 10], whereas others have shown no
association with prognosis [8, 16–19].
The primary aim of this study was therefore to determine
the prognostic significance of HER2 overexpression in
patients with operable oesophagogastric adenocarcinoma.
The secondary aim was to determine the accuracy of the
endoscopic index biopsy in assessing HER2 overexpression
when compared with the final operative resection specimen.
2. Methods
Eighty-five consecutive patients diagnosed with oesopha-
gogastric adenocarcinoma (18 oesophageal (OC), 32 junc-
tional (JC), and 35 gastric (GC)) undergoing R0 resection
between 1 February 2001 and 30 June 2006 were studied
retrospectively. All tumours were staged in accordance with
the International Union against Cancer tumour node metas-
tasis (TNM) classification of malignant tumours TNM6
[20]. The primary outcome measure was survival from
diagnosis. Ethical approval was obtained from the local ethics
committee.
2.1. Neoadjuvant Chemotherapy. The selective use of neoad-
juvant chemotherapy was adopted in the latter part of the
study period and was given to 25 patients with minimal
comorbidities who were deemed to have relatively advanced
disease and would benefit from downstaging of the tumour
prior to surgery. Chemotherapy was administered for three
or four cycles preoperatively and postoperatively. Each cycle
consisted of epirubicin (50mg/m2) by intravenous bolus,
cisplatin (60mg/m2) as a four-hour infusion on day 1
and 5-fluorouracil (200mg/m2/day) daily by a continuous
intravenous infusion.
2.2. Surgical Treatment. Patients with oesophageal cancer
were selected for radical treatment based on perceived
radiologic stage, comorbidity, and patient choice according
to algorithms described previously [21–23]. The type of
surgery for gastric cancer was determined by the anatomical
location of the tumour; subtotal gastrectomy was performed
in patients with antral tumours and total gastrectomy was
performed in tumours of the cardia (Siewert type III),
body, and linitis plastica. A modified D2 lymphadenectomy
preserving the spleen and pancreas was performed [24].
2.3. Immunohistochemistry. Immunohistochemistry (IHC)
was used to determine patients’ HER2 status at the endo-
scopic index biopsy and the final operative resection speci-
men. Sections (4 μm) of tissue were cut, mounted on coated
slides, labeled, and then placed on the Ventana Bench-
mark XT (Roche Diagnostics) for detection of the HER2
oncoprotein. The sections were dewaxed then subjected to
pretreatment with CC1 for 30 minutes. Sections were then
washed with reaction buﬀer followed by incubation with
the rabbit monoclonal primary antibody HER2/neu (clone
4B5, Pathway) for 16 minutes. On board detection using
ultraView Universal DAB kit (Roche Diagnostics), used in
accordance with the manufacturer’s recommendations, was
used to detect the location of the primary antibody HER2
followed by counterstain with haematoxylin II for 4 minutes
(Roche Diagnostics).
All sections were reviewed independently by two con-
sultant histopathologists (Jassani and Williams) who were
blinded to all clinical and pathological information. Discor-
dant cases were reviewed together and a final consensus was
reached. Evaluation and scoring of HER2 protein overex-
pression was performed according to the Dako HercepTest
scoring system for breast cancer. Only membranous staining
was considered. This scoring system has been validated for
use in gastric cancer with minimal modifications: 0/negative
= staining or membranous reactivity in <10% of cells,
1+/negative = faint membranous reactivity in >10% of cells
or cells with reactivity only in part of their membrane,
2+/equivocal = weak/moderate complete or basolateral
membranous staining in >10% of tumour cells; and 3+/pos-
itive = strong complete or basolateral membranous staining
in >10% of tumour cells [25, 26].
2.4. Follow-Up Evaluation. Patients were reviewed every 3
months for the first year, then every 6 months thereafter.
The median follow-up period was 71 months. A total of 79
patients (93%) were followed up for at least 5 years or until
death. Death certification was obtained from the Oﬃce for
National Statistics.
2.5. Statistical Analysis. Statistical analysis appropriate for
nonparametric data was used. Grouped data were expressed
as median (range). Groups were compared with the
Mann-Whitney U test for unpaired data. The agreement
between HER2 status at index biopsy and the postoperative
histopathological resection specimen was determined using
the weighted Kappa statistic (Kw) [27]. The value of Kappa
has a maximum of 1.00 when agreement is perfect, a value of
zero indicates no agreement better than chance and negative
values show worse than chance agreement. The strength
of agreement was assessed according to the guidelines of
Landis and Koch [27]. The sensitivity and specificity, positive
predictive value and negative predictive value were also
estimated. Cumulative survival was calculated by the life
table method of Kaplan and Meier [28]. Diﬀerences in
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Figure 1: Survival related to HER2 overexpression in all patients.
survival times between groups of patients were analysed by
the log rank method [29]. Multivariate Cox regression was
used to assess the prognostic value of individual variables.
Data analysis was carried out with the Statistical Package for
Social Sciences (SPSS) version 18 (SPSS, Chicago, Illinois,
USA).
3. Results
Twenty (24%) patients had HER2 positive tumours, and
positive HER2 status was commoner in JC (14/32, 44%
versus 2/18, 11% in OC and 4/35, 11% in GC; χ2 = 11.66,
P = 0.003), Table 1.
3.1. Accuracy of Biopsy in Determining HER2 Status. Com-
parison of HER2 expression status between the index biopsy
and final operative resection specimen revealed sensitivity,
specificity, and positive and negative predictive values were
56%, 93%, 63%, 91%, respectively. There was strong agree-
ment between the index biopsy and final operative resection
specimen (weighted Kappa statistic was 0.504; 95%CI 0.128–
0.856; P < 0.0001). Only 3 patients had a false positive biopsy
result, all of whom had undergone gastrectomy without
neoadjuvant chemotherapy.
3.2. Outcomes Related to HER2 Expression. Short-term out-
comes were similar in patients with HER2 positive and
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Figure 2: Survival related to HER2 overexpression in patients with
junctional adenocarcinoma.
negative tumours (Table 2). Cumulative five-year survival
related to HER2 status was 30% for the HER2 positive
cohort compared with 43% for the HER2 negative cohort
(P = 0.221), (Figure 1). With regard to tumour site, 5-year
survival in OC HER2 positive versus negative cohorts was
100% and 36% (P = 0.167) compared with 14% and 44%
(P = 0.0726) in JC (Figure 2) and 50% and 46% (P = 0.942)
in GC, respectively. Univariate analysis of factors associated
with duration of survival is shown in Table 3.
4. Discussion
HER2 overexpression was found in 24% of patients in
this cohort, the majority of whom had tumours situated
around the oesophagogastric junction. This is in keeping
with recent studies reporting a prevalence rate of 15–
30% [8, 11, 14]. The previously quoted range of 11–73%
largely originates from studies conducted in the 1990s which
adopted various cutoﬀs for the classification of HER2 status
preventing valid comparisons to be made [15, 30–32]. There
was a trend towards poorer long-term survival in patients
diagnosed with HER2 positive operable oesophagogastric
cancer compared to patients with HER2 negative tumours.
However, this diﬀerence was not statistically significant and
this finding echoes more recent reports which have also
shown that HER2 overexpression was not associated with
duration of survival [8, 12, 17, 33].
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The accuracy of endoscopic biopsy in determining HER2
status in oesophagogastric cancer has not been documented
previously. We report a high specificity and negative pre-
dictive value of endoscopic biopsy in determining HER2
status in oesophagogastric cancer. However, the sensitivity
and positive predictive value was lower when compared
with breast core-needle biopsies [34]. The pattern of HER2
staining in breast cancer tends to be homogenous, whereas
HER2 staining in gastric cancer is heterogeneous [26]. A
modified scoring system which only takes into account the
pattern of reactivity irrespective of the number of reactive
cells in biopsy specimens has therefore been introduced [26].
This study has several potential limitations. This was a
retrospective observational study and is therefore open to
selection bias. The relatively small sample size could have
resulted in a type II error. HER2 status was determined
using IHC on tissue samples which have been stored for
a few years prior to analysis. Deterioration in antigenicity
can occur once sections from paraﬃn blocks have been
put onto slides [35] and could arguably underestimate the
prevalence of HER2 overexpression in our cohort. However,
this appears to be a limitation of most studies published
on this subject [8, 16, 36]. Although the assessment of
HER2 gene amplification with in situ hybridisation (ISH)
techniques has been recommended to determine the final
HER2 status in equivocal IHC 2+ [26], we did not perform
ISH on the 5 patients in our cohort who had IHC 2+ as the
concordance between IHC and ISH have been shown to be
high [26, 37].
Conversely, the strengths of the study are that the
demographic data and outcomes were collected prospec-
tively, from a well-defined geographical area served by an
established regional upper GI network. The study’s survival
and prognostic data are especially robust because no patients
were lost to followup, and causes and exact dates of death
were obtained from death certificates provided by the Oﬃce
for National Statistics. HER2 status was determined by two
specialist consultant histopathologists, one of whom (B.J)
was part of the steering group recommending guidelines for
HER2 testing in the UK [25, 38, 39].
A larger prospective study using validated and repro-
ducible methods in IHC and ISH is needed to clarify
the prognostic role of HER2 in patients with operable
oesophagogastric cancer. The accuracy of the index biopsy
at determining HER2 status is important as the addition of
anti-HER2 therapy to the standard neoadjuvant chemother-
apy regime may be beneficial in HER2 positive patients.
Future studies into targeted molecular therapies should also
take into account characteristics of both the primary tumour
and disseminated tumour cells [8].
5. Conclusions
Endoscopic biopsy had a high specificity and negative
predictive value in determining HER2 status. Patients with
JC had a significantly higher rate of HER2 overexpression
and this was associated with a nonsignificant poorer survival
trend. A larger study is needed to confirm these findings
Table 1: Details of patients.
OC JC GC P value
Number 18 32 35
Median age (years) 60 66 72 0.012
Gender M : F (%)
18 : 0
(100 : 0)
27 : 5
(84 : 16)
19 : 16
(54 : 46)
<0.0001
Surgery (%)
TTO 7 (39) 9 (28) —
THO 11 (61) 13 (41) —
TG — 10 (31) 9 (26)
STG — — 26 (74)
HER2+ (%) 2 (11) 14 (44) 4 (11) 0.003
pTNM (%)
I and II 10 (56) 12 (37) 20 (57)
0.062
III and IV 8 (44) 20 (63) 15 (43)
OC: Oesophageal adenocarcinoma; JC: junctional adenocarcinoma; GC:
gastric adenocarcinoma; TTO: transthoracic oesophagectomy; THO: tran-
shiatal oesophagectomy; TG: total gastrectomy; STG: subtotal gastrectomy.
Table 2: Outcome related to HER2 overexpression.
HER2 − HER2+ P value
Number (%) 65 (76) 20 (24)
Median age (years) 66 69 0.705
Gender M : F (%) 48 : 17 (74 : 26) 16 : 4 (80 : 20) 0.577
pTNM (%)
I and II (52) (40)
0.089
III and IV (48) (60)
Morbidity (%) 23 (35) 7 (35) 0.975
Mortality (%) 2 (3) 1 (5) 0.47
Median survival (months) 43 27
0.221
1 year survival (%) 89 80
2 year survival (%) 61 55
5 year survival (%) 43 30
Table 3: Univariate analysis of factors associated with duration of
survival.
Factor χ2 df P value
HER2 overexpression 1.497 1 0.221
pT stage 17.346 3 0.001
Age 68.826 4 0.001
pN stage 34.272 3 <0.0001
pTNM stage 30.786 3 <0.0001
Lymph node ratio 183.926 3 <0.0001
because of the implications for neoadjuvant and adjuvant
chemotherapy regimens.
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